EXTENDED OPERATIONS AFTER INDUCTION THERAPY FOR STAGE IIIB (T4) NONSMALL CELL LUNG-CANCER

被引:54
作者
MACCHIARINI, P
CHAPELIER, AR
MONNET, I
VANNETZEL, JM
REBISCHUNG, JL
CERRINA, J
PARQUIN, F
LADURIE, FL
LENOT, B
DARTEVELLE, PG
机构
[1] Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Hôpital Marie-Lannelongue, Paris-Sud University, Le Plessis Robinson
关键词
D O I
10.1016/0003-4975(94)90215-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Twenty-three patients with stage IIIb (T4) non-small cell lung cancer received induction chemotherapy (median, 2 cycles) with (n = 12) or without (n = 11) radiation (median, 45 Gy) before operation. Nine tumors involved the carina (n = 8) or lateral tracheal wall (n = I), 11 were located centrally and invaded the proximal pulmonary artery (n = 6), veins (n = 3), or both (n = 2), three were apical tumors involving T4 structures, and six were associated with histologically diseased mediastinal nodes. Five complete and 18 partial responses were observed after induction treatment. Resection of all residual tumor at the primary site and involved vestiges was possible in 21 patients (91%); in two apical tumors, tumor was left behind. Nine right tracheal sleeve and 11 intrapericardial pneumonectomies and three resections of apical tumors were performed; 11 patients (48%) had radical mediastinal lymph node dissection. Complete sterilization of the primary tumor was observed in 3 patients (13%). Mean operating time was 209.3 +/- 86.8 minutes, and mean blood loss was 896.9 +/- 1031 mL. Major postoperative complications occurred in 6 patients (26%), including hemothorax requiring drainage (n = 1) or reoperation (n = 1), acute distress syndrome (n = 2), and bronchopleural fistula (n = 2), and their incidence was significantly higher (p = 0.003) among patients receiving induction chemoradiation than among those receiving chemotherapy alone (42 versus 9%). Early (<1 month) postoperative mortality was 8.6% (n = 2). With a median follow-up of 25 months (range, 12 to more than 39 months), the projected 3-year overall survival was 54%. Further follow-up will define whether this aggressive approach should become standard fare for selected IIIb (T4) non-small cell lung cancer patients.
引用
收藏
页码:966 / 973
页数:8
相关论文
共 31 条
[1]  
BLEHEEN NM, 1991, LUNG CANCER, V7, P85
[2]   INDUCTION CHEMOTHERAPY WITH MITOMYCIN, VINDESINE, AND CISPLATIN FOR STAGE-III UNRESECTABLE NON-SMALL-CELL LUNG-CANCER - RESULTS OF THE TORONTO PHASE-II TRIAL [J].
BURKES, RL ;
GINSBERG, RJ ;
SHEPHERD, FA ;
BLACKSTEIN, ME ;
GOLDBERG, ME ;
WATERS, PF ;
PATTERSON, GA ;
TODD, T ;
PEARSON, FG ;
COOPER, JD ;
JONES, D ;
LOCKWOOD, G .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :580-586
[3]  
BURT ME, 1987, SURG CLIN N AM, V67, P987
[4]  
COX DR, 1972, J R STAT SOC B, V34, P187
[5]  
DARTEVELLE PG, 1991, J THORAC CARDIOV SUR, V102, P259
[6]   ANTERIOR TRANSCERVICAL-THORACIC APPROACH FOR RADICAL RESECTION OF LUNG-TUMORS INVADING THE THORACIC INLET [J].
DARTEVELLE, PG ;
CHAPELIER, AR ;
MACCHIARINI, P ;
LENOT, B ;
CERRINA, J ;
LADURIE, FL ;
PARQUIN, FJF ;
LAFONT, D .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1993, 105 (06) :1025-1034
[7]   TRACHEAL SLEEVE PNEUMONECTOMY FOR BRONCHOGENIC-CARCINOMA - REPORT OF 55 CASES [J].
DARTEVELLE, PG ;
KHALIFE, J ;
CHAPELIER, A ;
MARZELLE, J ;
NAVAJAS, M ;
LEVASSEUR, P ;
ROJAS, A ;
CERRINA, J .
ANNALS OF THORACIC SURGERY, 1988, 46 (01) :68-72
[8]  
DEMEESTER TR, 1989, J THORAC CARDIOV SUR, V97, P373
[9]  
FISHER B, 1983, CANCER RES, V43, P1488
[10]   WHATS IN A NAME - NEOADJUVANT [J].
FREI, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (14) :1088-1089